This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Released: ·Last reviewed: ·Methodology v4.1
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.
GLP-1 dosing: how titration works
Quick answer
GLP-1 medications are started low and increased gradually — titration — to limit gastrointestinal side effects while reaching an effective dose. Exact schedules differ by molecule and brand and are set by the label and the prescribing clinician.
Why titration matters
Starting at a low dose and stepping up over weeks reduces nausea and other GI effects. Rushing titration is a common cause of intolerable side effects.
Label schedules
Each brand has an FDA-approved escalation schedule. Compounded programs may use different steps; a clinician should direct any deviation from label dosing.
Frequently asked questions
Can I speed up my GLP-1 dose increase?
Faster titration usually worsens side effects and should only happen under clinician direction. Follow your prescriber's schedule.
Sources
- U.S. Food and Drug Administration — labels and safety communications.
- Peer-reviewed clinical trials cited above.
- Our methodology and medical review policy.
How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.